The diagnostics advisory committee considered evidence on digital technologies for applying algorithms to spirometry from several sources. This included evidence submitted by 4 companies, a review of ...

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 ...

Denmark: A recent exploratory analysis published in Clinical Obesity has found that liraglutide, a GLP-1 receptor agonist ...

NICE's early-use assessment of digital technologies for applying algorithms to spirometry to support asthma and chronic obstructive pulmonary disorder diagnosis in primary care and community ...

Introduction to the Global Respiratory Diagnostics MarketThe global respiratory diagnostics market is projected to expand at a steady growth rate of approximately 7% over the next five years, ...

The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...

Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...

Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

AstraZenecaAZN stock jumped Friday after the U.K.-based drugmaker said its COPD drug succeeded in two final-phase studies. COPD, or chronic obstructive pulmonary disease, is a respiratory condition in ...